NCT01154244View on ClinicalTrials.gov

Insulin Resistance as Primary Pathogenesis in Newly Diagnosed, Drug naïve Type 2 Diabetes Patients in Korea

CompletedOBSERVATIONAL

Enrollment

1,439

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions

Diabetes Mellitus, Type 2

Interventions

OTHER

HOMA-IR

Blood sampling for HOMA-IR and HbA1C, fasting glucose, C-peptide, Lipid profile

Trial Locations (2)

150-713

GSK Investigational Site, Bucheon-si

110-749

GSK Investigational Site, Seoul

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY